CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INC: Form 990, tax year 2013

View the entire original 990 at ProPublica ↗

Organization: CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INC (EIN 91-2059167)
Tax period: 2013-01-01 to 2013-12-31
Filed: 2014-07-15
IRS object ID: 201441969349300614
Schema version: 2013v3.1
Source: Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header
Form 990
Schedule A
Schedule D
Schedule F
Schedule I
Schedule J
Schedule O
Schedule R

Return header ReturnHeader

Field	Value	IRS element (for citing)
Return	2014-07-15T08:55:35-05:00	ReturnTs
Tax Period End	2013-12-31	TaxPeriodEndDt

Preparer Firm PreparerFirmGrp

Preparer Firm Name PreparerFirmName

Field	Value	IRS element (for citing)
Business Name Line1	BDO USA LLP	BusinessNameLine1

Preparer US Address PreparerUSAddress

Field	Value	IRS element (for citing)
Address Line1	8405 GREENSBORO DRIVE 7TH FLOOR	AddressLine1
City	MCLEAN	City
State	VA	State
ZIP Code	22102	ZIPCode

Field	Value	IRS element (for citing)
Return Type	990	ReturnTypeCd
Tax Period Begin	2013-01-01	TaxPeriodBeginDt

Filer Filer

Field	Value	IRS element (for citing)
EIN	912059167	EIN

Business Name BusinessName

Field	Value	IRS element (for citing)
Business Name Line1	CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INC	BusinessNameLine1

Field	Value	IRS element (for citing)
In Care Of	% ROBERT J BEALL PHD	InCareOfNm
Business Name Control	CYST	BusinessNameControlTxt
Phone	3019514422	PhoneNum

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	6931 ARLINGTON ROAD	AddressLine1
Address Line2	Suite 200	AddressLine2
City	BETHESDA	City
State	MD	State
ZIP Code	20814	ZIPCode

Business Officer BusinessOfficerGrp

Field	Value	IRS element (for citing)
Person	ROBERT J BEALL PHD	PersonNm
Person Title	PRESIDENT & CEO	PersonTitleTxt
Phone	7038930600	PhoneNum
Signature	2014-06-30	SignatureDt
Discuss With Paid Preparer	Yes (true)	DiscussWithPaidPreparerInd

Preparer Person PreparerPersonGrp

Field	Value	IRS element (for citing)
Preparer Person	Jeffrey J Schragg	PreparerPersonNm
Phone	7038930600	PhoneNum

Field	Value	IRS element (for citing)
Tax	2013	TaxYr
Build TS	2015-11-30 17:44:51Z	BuildTS

Form 990 IRS990

Field	Value	IRS element (for citing)
Principal Officer	ROBERT J BEALL PHD	PrincipalOfficerNm

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	6931 ARLINGTON ROAD STE 200	AddressLine1
City	BETHESDA	City
State	MD	State
ZIP Code	20814	ZIPCode

Field	Value	IRS element (for citing)
Gross Receipts	$257,414,279	GrossReceiptsAmt
Group Return For Affiliates	false	GroupReturnForAffiliatesInd
Organization501c3	Yes (X)	Organization501c3Ind
Website Address	www.CFF.ORG/RESEARCH/CFFT/	WebsiteAddressTxt
Type Of Organization Corp	Yes (X)	TypeOfOrganizationCorpInd
Formation	2000	FormationYr
Legal Domicile State	MD	LegalDomicileStateCd
Activity Or Mission	THE MISSION IS TO CURE CYSTIC FIBROSIS AND TO PROVIDE ALL PEOPLE WITH THE DISEASE THE OPPORTUNITY TO LEAD FULL, PRODUCTIVE LIVES.	ActivityOrMissionDesc
Voting Members Governing Body	7	VotingMembersGoverningBodyCnt
Voting Members Independent	6	VotingMembersIndependentCnt
Total Employee	29	TotalEmployeeCnt
Total Volunteers	0	TotalVolunteersCnt
Total Gross UBI	$0	TotalGrossUBIAmt
Net Unrelated Bus Txbl Incm	$0	NetUnrelatedBusTxblIncmAmt
PY Contributions Grants	$0	PYContributionsGrantsAmt
CY Contributions Grants	$0	CYContributionsGrantsAmt
PY Program Service Revenue	$192,984	PYProgramServiceRevenueAmt
CY Program Service Revenue	$223,471	CYProgramServiceRevenueAmt
PY Investment Income	$0	PYInvestmentIncomeAmt
CY Investment Income	$0	CYInvestmentIncomeAmt
PY Other Revenue	$156,491,789	PYOtherRevenueAmt
CY Other Revenue	$257,190,808	CYOtherRevenueAmt
PY Total Revenue	$156,684,773	PYTotalRevenueAmt
CY Total Revenue	$257,414,279	CYTotalRevenueAmt
PY Grants And Similar Paid	$116,651,304	PYGrantsAndSimilarPaidAmt
CY Grants And Similar Paid	$210,196,981	CYGrantsAndSimilarPaidAmt
PY Benefits Paid To Members	$0	PYBenefitsPaidToMembersAmt
CY Benefits Paid To Members	$0	CYBenefitsPaidToMembersAmt
PY Salaries Comp Emp Bnft Paid	$3,695,781	PYSalariesCompEmpBnftPaidAmt
CY Salaries Comp Emp Bnft Paid	$4,951,732	CYSalariesCompEmpBnftPaidAmt
PY Total Prof Fndrsng Expns	$0	PYTotalProfFndrsngExpnsAmt
CY Total Prof Fndrsng Expns	$0	CYTotalProfFndrsngExpnsAmt
CY Total Fundraising Expense	$0	CYTotalFundraisingExpenseAmt
PY Other Expenses	$36,337,688	PYOtherExpensesAmt
CY Other Expenses	$42,265,566	CYOtherExpensesAmt
PY Total Expenses	$156,684,773	PYTotalExpensesAmt
CY Total Expenses	$257,414,279	CYTotalExpensesAmt
CY Revenues Less Expenses	$0	CYRevenuesLessExpensesAmt
Total Assets BOY	$41,843,226	TotalAssetsBOYAmt
Total Assets EOY	$55,984,395	TotalAssetsEOYAmt
Total Liabilities BOY	$41,843,226	TotalLiabilitiesBOYAmt
Total Liabilities EOY	$55,984,395	TotalLiabilitiesEOYAmt
Net Assets Or Fund Balances BOY	$0	NetAssetsOrFundBalancesBOYAmt
Net Assets Or Fund Balances EOY	$0	NetAssetsOrFundBalancesEOYAmt
Mission	THE MISSION OF THE CYSTIC FIBROSIS FOUNDATION, A NONPROFIT DONOR SUPPORTED ORGANIZATION, IS TO CURE CYSTIC FIBROSIS AND TO PROVIDE ALL PEOPLE WITH THE DISEASE THE OPPORTUNITY TO LEAD FULL, PRODUCTIVE LIVES BY FUNDING RESEARCH AND DRUG DEVELOPMENT AND PROMOTING INDIVIDUALIZED TREATMENT. A LIFE-SHORTENING GENETIC DISEASE, CF AFFECTS THE LUNGS AND DIGESTIVE SYSTEMS OF NEARLY 30,000 CHILDREN AND YOUNG ADULTS IN the U.S. CURRENTLY, THERE IS NO CURE. The mission is to cure cystic fibrosis and to provide all people with the disease the opportunity to lead full, productive lives.	MissionDesc
Significant New Program Srvc	false	SignificantNewProgramSrvcInd
Significant Change	false	SignificantChangeInd
Expense	$47,013,294	ExpenseAmt
Desc	Investments by Cystic Fibrosis Foundation Therapeutics (CFFT) in state-of-the-art research have accelerated progress toward developing new CF treatments and finding a cure for the disease. By funding CF drug discovery and development research conducted by biotechnology companies and providing matching awards to CF drug developers for CF research, and with a specialized CF clinical trials network, CFFT has attracted significant industry involvement in the fight against CF. CFFT accomplishes its mission by funding life-saving research to develop effective therapies for people with CF. CFFT has funded hundreds of millions of dollars of research costs to help develop CF drugs and therapies. Through CFFT's efforts, the life expectancy of people with CF has doubled in the last 30 years, and research to find a cure is more promising than ever before.	Desc

Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp

Field	Value	IRS element (for citing)
Expense	$209,668,066	ExpenseAmt
Grant	$40,497,213	GrantAmt
Revenue	$223,471	RevenueAmt
Desc	CFFT supports a national clinical research network consisting of nearly 80 CF Foundation-accredited care centers that collaborate to conduct clinical trials, allowing potential new CF therapies to move to larger, late-stage studies more quickly. Medical programs in 2013 consisted of costs to support scientific study and investigations. 141 grants were awarded in 2013.	Desc

Field	Value	IRS element (for citing)
Total Program Service Expenses	$256,681,360	TotalProgramServiceExpensesAmt
Described In Section501c3	Yes (true)	DescribedInSection501c3Ind
Schedule B Required	false	ScheduleBRequiredInd
Political Campaign Acty	false	PoliticalCampaignActyInd
Lobbying Activities	false	LobbyingActivitiesInd
Donor Advised Fund	false	DonorAdvisedFundInd
Conservation Easements	false	ConservationEasementsInd
Collections Of Art	false	CollectionsOfArtInd
Credit Counseling	false	CreditCounselingInd
Temp Or Permanent Endowments	false	TempOrPermanentEndowmentsInd
Report Land Building Equipment	Yes (true)	ReportLandBuildingEquipmentInd
Report Investments Other Sec	false	ReportInvestmentsOtherSecInd
Report Program Related Invst	false	ReportProgramRelatedInvstInd
Report Other Assets	Yes (true)	ReportOtherAssetsInd
Report Other Liabilities	false	ReportOtherLiabilitiesInd
Include FIN48 Footnote	false	IncludeFIN48FootnoteInd
Independent Audit Fincl Stmt	false	IndependentAuditFinclStmtInd
Consolidated Audit Fincl Stmt	Yes (true)	ConsolidatedAuditFinclStmtInd
School Operating	false	SchoolOperatingInd
Foreign Office	false	ForeignOfficeInd
Foreign Activities	Yes (true)	ForeignActivitiesInd
More Than5000 K To Org	Yes (true)	MoreThan5000KToOrgInd
More Than5000 K To Individuals	false	MoreThan5000KToIndividualsInd
Professional Fundraising	false	ProfessionalFundraisingInd
Fundraising Activities	false	FundraisingActivitiesInd
Gaming Activities	false	GamingActivitiesInd
Operate Hospital	false	OperateHospitalInd
Grants To Organizations	Yes (true)	GrantsToOrganizationsInd
Grants To Individuals	false	GrantsToIndividualsInd
Schedule J Required	Yes (true)	ScheduleJRequiredInd
Tax Exempt Bonds	false	TaxExemptBondsInd
Engaged In Excess Benefit Trans	false	EngagedInExcessBenefitTransInd
PY Excess Benefit Trans	false	PYExcessBenefitTransInd
Loan Outstanding	false	LoanOutstandingInd
Grant To Related Person	false	GrantToRelatedPersonInd
Business Rln With Org Mem	false	BusinessRlnWithOrgMemInd
Business Rln With Fam Mem	false	BusinessRlnWithFamMemInd
Business Rln With Officer Ent	false	BusinessRlnWithOfficerEntInd
Deductible Non Cash Contri	false	DeductibleNonCashContriInd
Deductible Art Contribution	false	DeductibleArtContributionInd
Terminate Operations	false	TerminateOperationsInd
Partial Liquidation	false	PartialLiquidationInd
Disregarded Entity	false	DisregardedEntityInd
Related Entity	Yes (true)	RelatedEntityInd
Related Organization Ctrl Ent	false	RelatedOrganizationCtrlEntInd
Trnsfr Exmpt Non Chrtbl Rltd Org	false	TrnsfrExmptNonChrtblRltdOrgInd
Activities Conducted Prtshp	false	ActivitiesConductedPrtshpInd
Schedule O Required	Yes (true)	ScheduleORequiredInd
IRP Document	74	IRPDocumentCnt
IRP Document W2 G	0	IRPDocumentW2GCnt
Backup Wthld Compliance	Yes (true)	BackupWthldComplianceInd
Employee	29	EmployeeCnt
Employment Tax Returns Filed	Yes (true)	EmploymentTaxReturnsFiledInd
Unrelated Bus Incm Over Limit	false	UnrelatedBusIncmOverLimitInd
Foreign Financial Account	false	ForeignFinancialAccountInd
Prohibited Tax Shelter Trans	false	ProhibitedTaxShelterTransInd
Taxable Party Notification	false	TaxablePartyNotificationInd
Nondeductible Contributions	false	NondeductibleContributionsInd
Quid Pro Quo Contributions	false	QuidProQuoContributionsInd
Form8282 Property Disposed Of	false	Form8282PropertyDisposedOfInd
Rcv Fnds To Pay Prsnl Bnft Cntrct	false	RcvFndsToPayPrsnlBnftCntrctInd
Pay Premiums Prsnl Bnft Cntrct	false	PayPremiumsPrsnlBnftCntrctInd
Indoor Tanning Services	false	IndoorTanningServicesInd
Info In Schedule O Part VI	Yes (X)	InfoInScheduleOPartVIInd
Governing Body Voting Members	7	GoverningBodyVotingMembersCnt
Independent Voting Member	6	IndependentVotingMemberCnt
Family Or Business Rln	false	FamilyOrBusinessRlnInd
Delegation Of Mgmt Duties	false	DelegationOfMgmtDutiesInd
Change To Org Documents	false	ChangeToOrgDocumentsInd
Material Diversion Or Misuse	false	MaterialDiversionOrMisuseInd
Members Or Stockholders	false	MembersOrStockholdersInd
Election Of Board Members	Yes (true)	ElectionOfBoardMembersInd
Decisions Subject To Approva	false	DecisionsSubjectToApprovaInd
Minutes Of Governing Body	Yes (true)	MinutesOfGoverningBodyInd
Minutes Of Committees	Yes (true)	MinutesOfCommitteesInd
Officer Mailing Address	false	OfficerMailingAddressInd
Local Chapters	false	LocalChaptersInd
Form990 Provided To Gvrn Body	Yes (true)	Form990ProvidedToGvrnBodyInd
Conflict Of Interest Policy	Yes (true)	ConflictOfInterestPolicyInd
Annual Disclosure Covered Prsn	Yes (true)	AnnualDisclosureCoveredPrsnInd
Regular Monitoring Enfrc	Yes (true)	RegularMonitoringEnfrcInd
Whistleblower Policy	Yes (true)	WhistleblowerPolicyInd
Document Retention Policy	Yes (true)	DocumentRetentionPolicyInd
Compensation Process CEO	Yes (true)	CompensationProcessCEOInd
Compensation Process Other	Yes (true)	CompensationProcessOtherInd
Investment In Joint Venture	false	InvestmentInJointVentureInd
States Where Copy Of Return Is Fld	MI	StatesWhereCopyOfReturnIsFldCd
Own Website	Yes (X)	OwnWebsiteInd
Upon Request	Yes (X)	UponRequestInd

Books In Care Of Detail BooksInCareOfDetail

Field	Value	IRS element (for citing)
Person	ROBERT J BEALL PHD	PersonNm
Phone	3019514422	PhoneNum

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	6931 ARLINGTON ROAD STE 200	AddressLine1
City	BETHESDA	City
State	MD	State
ZIP Code	20814	ZIPCode

Form990 Part VII Section A Form990PartVIISectionAGrp (15 entries)

TitleTitleTxt	Average Hours Per WeekAverageHoursPerWeekRt	Average Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRt	Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd	Reportable Comp From OrgReportableCompFromOrgAmt	Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt	Other CompensationOtherCompensationAmt	OfficerOfficerInd	Highest Compensated EmployeeHighestCompensatedEmployeeInd
Christy Shaffer PHD
CHAIR	5.0	6.0	Yes (X)	$0	$0	$0
JASON M ARYEH
DIRECTOR	3.0		Yes (X)	$0	$0	$0
STEVEN SHAK MD
DIRECTOR	3.0	6.0	Yes (X)	$0	$0	$0
CATHERINE C MCLOUD
DIRECTOR	3.0	11.0	Yes (X)	$0	$0	$0
JONATHAN COHN MD
director	3.0		Yes (X)	$0	$0	$0
D Paul Flessner
Director	3.0		Yes (X)	$0	$0	$0
Robert J Beall PhD
President & CEO	20.0	40.0	Yes (X)	$364,564	$737,313	$261,787	Yes (X)
Preston W Campbell MD
Exec VP of Medical Affairs	20.0	40.0		$394,239	$796,908	$202,914	Yes (X)
C Richard Mattingly
Exec VP, COO AND SECRETARY	5.0	55.0		$0	$752,470	$220,754	Yes (X)
Vera H Twigg
EXEC VP and CFO	5.0	55.0		$0	$486,851	$91,349	Yes (X)
BRUCE MARSHALL MD
VP OF CLINICAL AFFAIRS	50.0			$379,325	$0	$31,552		Yes (X)
THEODORE J TORPHY PHD
HEAD OF RESEARCH STRATEGY	16.0			$215,600	$0	$0		Yes (X)
MARTIN MENSE
PRINCIPAL SCIENTIST DRUG DISC	50.0			$185,473	$0	$42,920		Yes (X)
Hermann Bihler PHD
Senior Scientist	50.0			$146,553	$0	$12,989		Yes (X)
CYNTHIA GEORGE MSN FNP BC
DIR OF CLINICAL RES RESOURCES	50.0			$127,454	$0	$13,478		Yes (X)

Field	Value	IRS element (for citing)
Total Reportable Comp From Org	$1,813,208	TotalReportableCompFromOrgAmt
Tot Reportable Comp Rltd Org	$2,773,542	TotReportableCompRltdOrgAmt
Total Other Compensation	$877,743	TotalOtherCompensationAmt
Indiv Rcvd Greater Than100 K	12	IndivRcvdGreaterThan100KCnt
Former Ofcr Employees Listed	false	FormerOfcrEmployeesListedInd
Total Comp Greater Than150 K	Yes (true)	TotalCompGreaterThan150KInd
Compensation From Other Srcs	false	CompensationFromOtherSrcsInd

Contractor Compensation ContractorCompensationGrp (5 entries)

Address Line1ContractorAddress/USAddress/AddressLine1	CityContractorAddress/USAddress/City	StateContractorAddress/USAddress/State	ZIP CodeContractorAddress/USAddress/ZIPCode	ServicesServicesDesc	CompensationCompensationAmt
VERTEX PHARMACEUTICALS LLC
50 NORTHERN AVENUE	BOSTON	MA	02210	CONTRACTED RESEARCH	$20,281,486
PFIZER INC
200 CAMBRIDGEPARK DR	CAMBRIDGE	MA	02140	contracted research	$10,449,569
PROTEOSTASIS THERAPEUTICS INC
200 TECHNOLOGY SQUARE	CAMBRIDGE	MA	02139	CONTRACTED RESEARCH	$2,070,083
CHANTEST INC
14556 NEO PARKWAY	CLEVELAND	OH	44128	RESEARCH SUPPORT	$1,950,000
MORGAN STANLEY CO LLC
1 PIERREPONT PLAZA 7TH FLOOR	BROOKLYN	NY	11201	transaction advisory	$1,879,333

Field	Value	IRS element (for citing)
Cntrct Rcvd Greater Than100 K	14	CntrctRcvdGreaterThan100KCnt
Total Contributions	$0	TotalContributionsAmt

Program Service Revenue ProgramServiceRevenueGrp (2 entries)

DescDesc	BusinessBusinessCd	Total Revenue ColumnTotalRevenueColumnAmt	Related Or Exempt Func IncomeRelatedOrExemptFuncIncomeAmt
CLINICAL STUDY	541900	$108,410	$108,410
REFUNDED OR CANCELLED GRANTS	900099	$115,061	$115,061

Field	Value	IRS element (for citing)
Total Program Service Revenue	$223,471	TotalProgramServiceRevenueAmt

Investment Income InvestmentIncomeGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$0	TotalRevenueColumnAmt

Incm From Invest Bond Proceeds IncmFromInvestBondProceedsGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$0	TotalRevenueColumnAmt

Royalties Revenue RoyaltiesRevenueGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$257,190,808	TotalRevenueColumnAmt
Exclusion	$257,190,808	ExclusionAmt

Rental Income Or Loss RentalIncomeOrLossGrp

Field	Value	IRS element (for citing)
Real	$0	RealAmt
Personal	$0	PersonalAmt

Net Rental Income Or Loss NetRentalIncomeOrLossGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$0	TotalRevenueColumnAmt

Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$0	TotalRevenueColumnAmt

Net Incm From Fundraising Evt NetIncmFromFundraisingEvtGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$0	TotalRevenueColumnAmt

Net Income From Gaming NetIncomeFromGamingGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$0	TotalRevenueColumnAmt

Net Income Or Loss NetIncomeOrLossGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$0	TotalRevenueColumnAmt

Field	Value	IRS element (for citing)
Other Revenue Total	$0	OtherRevenueTotalAmt

Total Revenue TotalRevenueGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$257,414,279	TotalRevenueColumnAmt
Related Or Exempt Func Income	$223,471	RelatedOrExemptFuncIncomeAmt
Exclusion	$257,190,808	ExclusionAmt

Grants To Domestic Orgs GrantsToDomesticOrgsGrp

Field	Value	IRS element (for citing)
Total	$207,414,076	TotalAmt
Program Services	$207,414,076	ProgramServicesAmt

Grants To Domestic Individuals GrantsToDomesticIndividualsGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Foreign Grants ForeignGrantsGrp

Field	Value	IRS element (for citing)
Total	$2,782,905	TotalAmt
Program Services	$2,782,905	ProgramServicesAmt

Benefits To Members BenefitsToMembersGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp

Field	Value	IRS element (for citing)
Total	$880,483	TotalAmt
Program Services	$784,935	ProgramServicesAmt
Management And General	$95,548	ManagementAndGeneralAmt

Comp Disqual Persons CompDisqualPersonsGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Other Salaries And Wages OtherSalariesAndWagesGrp

Field	Value	IRS element (for citing)
Total	$3,570,839	TotalAmt
Program Services	$3,183,340	ProgramServicesAmt
Management And General	$387,499	ManagementAndGeneralAmt

Pension Plan Contributions PensionPlanContributionsGrp

Field	Value	IRS element (for citing)
Total	$185,148	TotalAmt
Program Services	$165,056	ProgramServicesAmt
Management And General	$20,092	ManagementAndGeneralAmt

Other Employee Benefits OtherEmployeeBenefitsGrp

Field	Value	IRS element (for citing)
Total	$40,949	TotalAmt
Program Services	$36,505	ProgramServicesAmt
Management And General	$4,444	ManagementAndGeneralAmt

Payroll Taxes PayrollTaxesGrp

Field	Value	IRS element (for citing)
Total	$274,313	TotalAmt
Program Services	$242,412	ProgramServicesAmt
Management And General	$31,901	ManagementAndGeneralAmt

Fees For Services Management FeesForServicesManagementGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Fees For Services Legal FeesForServicesLegalGrp

Field	Value	IRS element (for citing)
Total	$256,886	TotalAmt
Program Services	$256,886	ProgramServicesAmt

Fees For Services Accounting FeesForServicesAccountingGrp

Field	Value	IRS element (for citing)
Total	$3,850	TotalAmt
Management And General	$3,850	ManagementAndGeneralAmt

Fees For Services Lobbying FeesForServicesLobbyingGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Fees For Services Prof Fundraising FeesForServicesProfFundraising

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Fees For Services Other FeesForServicesOtherGrp

Field	Value	IRS element (for citing)
Total	$82,970	TotalAmt
Program Services	$55,962	ProgramServicesAmt
Management And General	$27,008	ManagementAndGeneralAmt

Advertising AdvertisingGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Office Expenses OfficeExpensesGrp

Field	Value	IRS element (for citing)
Total	$641,423	TotalAmt
Program Services	$605,065	ProgramServicesAmt
Management And General	$36,358	ManagementAndGeneralAmt

Information Technology InformationTechnologyGrp

Field	Value	IRS element (for citing)
Total	$642,349	TotalAmt
Program Services	$595,409	ProgramServicesAmt
Management And General	$46,940	ManagementAndGeneralAmt

Royalties RoyaltiesGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Occupancy OccupancyGrp

Field	Value	IRS element (for citing)
Total	$570,661	TotalAmt
Program Services	$521,691	ProgramServicesAmt
Management And General	$48,970	ManagementAndGeneralAmt

Travel TravelGrp

Field	Value	IRS element (for citing)
Total	$149,288	TotalAmt
Program Services	$139,506	ProgramServicesAmt
Management And General	$9,782	ManagementAndGeneralAmt

Pymt Travel Entrtnmnt Pub Ofcl PymtTravelEntrtnmntPubOfclGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Conferences Meetings ConferencesMeetingsGrp

Field	Value	IRS element (for citing)
Total	$89,110	TotalAmt
Program Services	$83,897	ProgramServicesAmt
Management And General	$5,213	ManagementAndGeneralAmt

Interest InterestGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Payments To Affiliates PaymentsToAffiliatesGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Depreciation Depletion DepreciationDepletionGrp

Field	Value	IRS element (for citing)
Total	$274,164	TotalAmt
Program Services	$265,437	ProgramServicesAmt
Management And General	$8,727	ManagementAndGeneralAmt

Insurance InsuranceGrp

Field	Value	IRS element (for citing)
Total	$139,624	TotalAmt
Program Services	$139,624	ProgramServicesAmt

Other Expenses OtherExpensesGrp (4 entries)

DescDesc	TotalTotalAmt	Program ServicesProgramServicesAmt	Management And GeneralManagementAndGeneralAmt	FundraisingFundraisingAmt
CONTRACTED RESEARCH	$38,740,581	$38,740,581
CHEMISTRY	$151,560	$151,560
MEDICAL ADVISORY FEES	$360,989	$360,989
MISCELLANEOUS	$162,111	$155,524	$6,587	$0

Total Functional Expenses TotalFunctionalExpensesGrp

Field	Value	IRS element (for citing)
Total	$257,414,279	TotalAmt
Program Services	$256,681,360	ProgramServicesAmt
Management And General	$732,919	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Cash Non Interest Bearing CashNonInterestBearingGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Savings And Temp Cash Invst SavingsAndTempCashInvstGrp

Field	Value	IRS element (for citing)
BOY	$3,343,624	BOYAmt
EOY	$4,019,774	EOYAmt

Pledges And Grants Receivable PledgesAndGrantsReceivableGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Accounts Receivable AccountsReceivableGrp

Field	Value	IRS element (for citing)
BOY	$441,065	BOYAmt
EOY	$412,310	EOYAmt

Receivables From Officers Etc ReceivablesFromOfficersEtcGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Rcvbl From Disqualified Prsn RcvblFromDisqualifiedPrsnGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Oth Notes Loans Receivable Net OthNotesLoansReceivableNetGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Inventories For Sale Or Use InventoriesForSaleOrUseGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp

Field	Value	IRS element (for citing)
BOY	$131,119	BOYAmt
EOY	$278,678	EOYAmt

Field	Value	IRS element (for citing)
Land Bldg Equip Cost Or Other Bss	$1,665,274	LandBldgEquipCostOrOtherBssAmt
Land Bldg Equip Accum Deprec	$611,478	LandBldgEquipAccumDeprecAmt

Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp

Field	Value	IRS element (for citing)
BOY	$704,389	BOYAmt
EOY	$1,053,796	EOYAmt

Investments Pub Traded Sec InvestmentsPubTradedSecGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Investments Other Securities InvestmentsOtherSecuritiesGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Investments Program Related InvestmentsProgramRelatedGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Intangible Assets IntangibleAssetsGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Other Assets Total OtherAssetsTotalGrp

Field	Value	IRS element (for citing)
BOY	$37,223,029	BOYAmt
EOY	$50,219,837	EOYAmt

Total Assets TotalAssetsGrp

Field	Value	IRS element (for citing)
BOY	$41,843,226	BOYAmt
EOY	$55,984,395	EOYAmt

Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp

Field	Value	IRS element (for citing)
BOY	$1,505,408	BOYAmt
EOY	$1,148,106	EOYAmt

Grants Payable GrantsPayableGrp

Field	Value	IRS element (for citing)
BOY	$40,337,818	BOYAmt
EOY	$54,836,289	EOYAmt

Deferred Revenue DeferredRevenueGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Tax Exempt Bond Liabilities TaxExemptBondLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Escrow Account Liability EscrowAccountLiabilityGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Loans From Officers Directors LoansFromOfficersDirectorsGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Mortg Notes Pybl Scrd Invst Prop MortgNotesPyblScrdInvstPropGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Unsecured Notes Loans Payable UnsecuredNotesLoansPayableGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Other Liabilities OtherLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Total Liabilities TotalLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$41,843,226	BOYAmt
EOY	$55,984,395	EOYAmt

Field	Value	IRS element (for citing)
Organization Follows SFAS117	Yes (X)	OrganizationFollowsSFAS117Ind

Unrestricted Net Assets UnrestrictedNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Temporarily Rstr Net Assets TemporarilyRstrNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Permanently Rstr Net Assets PermanentlyRstrNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp

Field	Value	IRS element (for citing)
BOY	$41,843,226	BOYAmt
EOY	$55,984,395	EOYAmt

Field	Value	IRS element (for citing)
Reconcilation Revenue Expnss	$0	ReconcilationRevenueExpnssAmt
Method Of Accounting Accrual	Yes (X)	MethodOfAccountingAccrualInd
Accountant Compile Or Review	false	AccountantCompileOrReviewInd
FS Audited	Yes (true)	FSAuditedInd

FS Audited Basis FSAuditedBasisGrp

Field	Value	IRS element (for citing)
Consolidated Basis Fincl Stmt	Yes (X)	ConsolidatedBasisFinclStmtInd

Field	Value	IRS element (for citing)
Audit Committee	Yes (true)	AuditCommitteeInd
Federal Grant Audit Required	false	FederalGrantAuditRequiredInd

Schedule A IRS990ScheduleA

Field	Value	IRS element (for citing)
Supporting Organization509a3	Yes (X)	SupportingOrganization509a3Ind
Supporting Org Type1	Yes (X)	SupportingOrgType1Ind
Certification	Yes (X)	CertificationInd
Contribution Controller	false	ContributionControllerInd
Contribution Family	false	ContributionFamilyInd
Contribution35 Controlled	false	Contribution35ControlledInd

Supported Org Information SupportedOrgInformationGrp

Supported Organization Name SupportedOrganizationName

Field	Value	IRS element (for citing)
Business Name Line1	CYSTIC FIBROSIS FOUNDATION	BusinessNameLine1

Field	Value	IRS element (for citing)
EIN	131930701	EIN
Organization Type	07	OrganizationTypeDesc
Governing Document Listed	Yes (true)	GoverningDocumentListedInd
Supported Org Notified	Yes (true)	SupportedOrgNotifiedInd
US Organized	Yes (true)	USOrganizedInd
Support	$169,699,768	SupportAmt

Field	Value	IRS element (for citing)
Supported Organizations Total	1	SupportedOrganizationsTotalCnt
Support Sum	$169,699,768	SupportSumAmt

Schedule D IRS990ScheduleD

Field	Value	IRS element (for citing)
Art Public Exhibition Amounts		ArtPublicExhibitionAmountsGrp
Held Works Art		HeldWorksArtGrp
CY Minus3 Yr Endwmt Fund		CYMinus3YrEndwmtFundGrp
CY Minus4 Yr Endwmt Fund		CYMinus4YrEndwmtFundGrp
Land		LandGrp
Buildings		BuildingsGrp
Leasehold Improvements		LeaseholdImprovementsGrp

Equipment EquipmentGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$1,665,274	OtherCostOrOtherBasisAmt
Depreciation	$611,478	DepreciationAmt
Book Value	$1,053,796	BookValueAmt

Field	Value	IRS element (for citing)
Other Land Buildings		OtherLandBuildingsGrp
Total Book Value Land Buildings	$1,053,796	TotalBookValueLandBuildingsAmt

Other Assets Org OtherAssetsOrgGrp

Field	Value	IRS element (for citing)
Desc	INTERCOMPANY RECEIVABLE	Desc
Book Value	$50,219,837	BookValueAmt

Field	Value	IRS element (for citing)
Total Book Value Other Assets	$50,219,837	TotalBookValueOtherAssetsAmt

Schedule F IRS990ScheduleF

Field	Value	IRS element (for citing)
Grant Records Maintained	Yes (true)	GrantRecordsMaintainedInd

Account Activities Outside US AccountActivitiesOutsideUSGrp (4 entries)

RegionRegionTxt	Type Of Activities ConductedTypeOfActivitiesConductedTxt	Specific Services ProvidedSpecificServicesProvidedTxt	Region Total ExpendituresRegionTotalExpendituresAmt
North America	Grantmaking	NONE	$930,649
Europe (Including Iceland and Greenland)	Grantmaking	none	$871,282
East Asia and the Pacific	Grantmaking	none	$754,963
Middle East and North Africa	Grantmaking	none	$226,011

Field	Value	IRS element (for citing)
Subtotal Spent	$2,782,905	SubtotalSpentAmt
Total Spent	$2,782,905	TotalSpentAmt

Grants To Org Outside US GrantsToOrgOutsideUSGrp (12 entries)

RegionRegionTxt	Purpose Of GrantPurposeOfGrantTxt	Cash GrantCashGrantAmt	Manner Of Cash DisbursementMannerOfCashDisbursementTxt
North America	DRUG DISCOVERY	$262,660	CHECK
North America	FUNCT'L GENO	$72,706	CHECK
North America	DRUG DISCOVERY	$216,000	CHECK
North America	CLINICAL RESEARCH	$379,283	CHECK
Europe (Including Iceland and Greenland)	CLINICAL RESEARCH	$60,000	WIRE
Europe (Including Iceland and Greenland)	CLINICAL RESEARCH	$114,785	WIRE
Europe (Including Iceland and Greenland)	DRUG DISCOVERY	$146,363	WIRE
Europe (Including Iceland and Greenland)	DRUG DISCOVERY	$356,652	WIRE
Europe (Including Iceland and Greenland)	DRUG DISCOVERY	$193,482	WIRE
Europe (Including Iceland and Greenland)	CLINICAL RESEARCH	$754,963	WIRE
Middle East and North Africa	DRUG DISCOVERY	$55,332	WIRE
Middle East and North Africa	DRUG DISCOVERY	$170,679	WIRE

Field	Value	IRS element (for citing)
Total501c3 Org	11	Total501c3OrgCnt
Transfer To Foreign Corp	false	TransferToForeignCorpInd
Interest In Foreign Trust	false	InterestInForeignTrustInd
Foreign Corp Ownership	false	ForeignCorpOwnershipInd
Passive Foreign Investmest Co	false	PassiveForeignInvestmestCoInd
Foreign Partnership	false	ForeignPartnershipInd
Boycott Countries	false	BoycottCountriesInd

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	Schedule F, Part I, Line 2	FormAndLineReferenceDesc
Explanation	THE ORGANIZATION HAS PROCEDURES IN PLACE TO MONITOR THE SCIENTIFIC PROGRESS AND FINANCIAL ASPECTS OF GRANTS AWARDED TO ENTITIES OUTSIDE OF THE UNITED STATES. THE ORGANIZATION FOLLOWS THE U.S. DEPARTMENT OF TREASURY ANTI-TERRORIST FINANCING VOLUNTARY BEST PRACTICES GUIDELINES FOR CHARITIES. IN COMPLIANCE WITH THE BEST PRACTICES, THE ORGANIZATION COLLECTS AND REVIEWS INFORMATION ABOUT THE PROSPECTIVE GRANTEES AND CONDUCTS A VETTING PROCESS TO ENSURE THEY ARE NOT SUSPECTED OF ACTIVITIES RELATED TO TERRORISM. ONCE A GRANT IS APPROVED, A WRITTEN AGREEMENT IS SIGNED BY BOTH THE ORGANIZATION AND THE GRANTEE. FUNDING IS INCREMENTAL AND SPONSORED INSTITUTIONS ARE REQUIRED TO SUBMIT ANNUAL REPORTS OF EXPENDITURES AS WELL AS SCIENTIFIC PROGRESS REPORTS. SCIENTIFIC REPORTS ARE REVIEWED BY THE ORGANIZATION'S SCIENTIFIC STAFF TO DETERMINE PROGRESS. THE FINAL GRANT PAYMENT IS CONTINGENT UPON RECEIPT AND APPROVAL OF THE REPORT OF EXPENDITURES. REPORTS OF EXPENDITURES ARE REVIEWED AND APPROVED BY STAFF TO ENSURE INCURRED COSTS ARE APPROPRIATE. INTERNAL AUDITORS CONDUCT AUDITS ON SAMPLES OF GRANT EXPENDITURE REPORTS BY EXAMINING SUPPORTING RECORDS FROM THE SPONSORED INSTITUTIONS. THE GRANTS IN THE MIDDLE EAST/NORTH AFRICA REGION WERE MADE TO BAR-ILAN UNIVERSITY and hebrew university of jerusalem, UNIVERSITies IN ISRAEL.	ExplanationTxt

Schedule I IRS990ScheduleI

Field	Value	IRS element (for citing)
Grant Records Maintained	Yes (true)	GrantRecordsMaintainedInd

Recipient Table RecipientTable (129 entries)

Address Line1USAddress/AddressLine1	Address Line2USAddress/AddressLine2	CityUSAddress/City	StateUSAddress/State	ZIP CodeUSAddress/ZIPCode	Recipient EINRecipientEIN	IRC SectionIRCSectionDesc	Cash GrantCashGrantAmt	Purpose Of GrantPurposeOfGrantTxt
Ann and Robert H Lurie Children's Hospital of Chi
2300 Childrens Plaza	Box 43	Chicago	IL	60614	363357006	501c(3)	$267,733	Clinical Res. Cntr
Arizona Board of Regents University of Arizona
Sponsored Projects Services	888 N Euclid Room 510	Tucson	AZ	85722	742652689	IRC 115	$138,999	Clinical Res. Cntr
Arizona Board of Regents University of Arizona
Sponsored Projects Services	888 N Euclid Room 510	Tucson	AZ	85722	742652689	IRC 115	$129,193	CLINICAL RESEARCH STUDY
Atlantic Health System
100 Madison Avenue		Morristown	NJ	07962	521958352	501c(3)	$141,966	Clinical Res. Cntr
Baylor College of Medicine
PO Box 1		Houston	TX	77212	741613878	501c(3)	$304,501	Clinical Res. Cntr
Beth Israel Medical Center
Office of Grants Contracts		New York	NY	10038	135564934	501c(3)	$164,246	Clinical Res. Cntr
Beth Israel Medical Center
Office of Grants Contracts	160 Water Street 24th Floor	New York	NY	10038	135564934	501c(3)	$149,354	CLINICAL RESEARCH STUDY
Board of Regents of the University of Wisconsin Sy
Research and Sponsored Programs	160 Water Street 24th Floor	Madison	WI	537151218	396006492	501c(3)	$145,293	Clinical Res. Cntr
Board of Regents of the University of Wisconsin Sy
750 University Avenue	21 N Park Street Suite 6401	Madison	WI	53706	396006492	501c(3)	$150,756	CLINICAL RESEARCH STUDY
Board of Trustees of the Leland Stanford Junior Un
Stanford University		Stanford	CA	943056215	941156365	501c(3)	$108,000	DRUG DISCOVERY AWARD
Board of Trustees of the Leland Stanford Junior Un
Stanford University	651 Serra Street Suite 220	Stanford	CA	943056215	941156365	501c(3)	$210,329	Clinical Res. Cntr
Board of Trustees of the Leland Stanford Junior Un
Stanford University		Stanford	CA	943056215	941156365	501c(3)	$114,206	CLINICAL RESEARCH STUDY
Boston Children's Hospital
300 Longwood Avenue	651 Serra Street Suite 220	Boston	MA	02115	042774441	501c(3)	$19,872	CLINICAL RESEARCH STUDY
Case Western Reserve University
10900 Euclid Avenue		Cleveland	OH	441067015	341018992	501c(3)	$411,480	Clinical Res. Cntr
Case Western Reserve University
10900 Euclid Avenue		Cleveland	OH	441067015	341018992	501c(3)	$107,980	CLINICAL RESEARCH STUDY
Central Florida Pulmonary Group
326 North Mills Avenue		Orlando	FL	32803	591760017	501c(3)	$91,276	Clinical Res. Cntr
Children's & Women's Physicians of Westchester LL
Pediatrics Department		Valhalla	NY	10595	133940462	501c(3)	$147,257	Clinical Res. Cntr
Children's Health Care
2525 Chicago Avenue South	Munger Pavilion Room 123	Minneapolis	MN	554041844	411754276	501c(3)	$130,247	Clinical Res. Cntr
Children's Hospital Corporation
300 Longwood Avenue		Boston	MA	02115	042774441	501c(3)	$359,934	Clinical Res. Cntr
Children's Hospital Medical Center
Cincinnati Childrens Hospital Med		Cincinnati	OH	45229	310833936	501c(3)	$23,136	ACADEMIC ADVISORY AWARD
Children's Hospital Medical Center
Cincinnati Childrens Hospital Med	3333 Burnet Avenue	Cincinnati	OH	45229	310833936	501c(3)	$229,667	Clinical Res. Cntr
Children's Hospital Medical Center of Akron
1 Perkins Square	3333 Burnet Avenue	Akron	OH	44308	340714357	501c(3)	$167,141	Clinical Res. Cntr
Children's Hospital Los Angeles
4650 Sunset Blvd		Los Angeles	CA	90027	951690977	501c(3)	$153,884	Clinical Res. Cntr
Children's Medical Center
One Childrens Plaza		Dayton	OH	45404	310672132	501c(3)	$136,591	Clinical Res. Cntr
Connecticut Children's Medical Center
282 Washington Street		Hartford	CT	06106	060646755	501c(3)	$124,035	Clinical Res. Cntr
Cook Children's Medical Center
801 Seventh Avenue		Ft Worth	TX	76104	752051646	501c(3)	$152,617	Clinical Res. Cntr
Cystic Fibrosis Foundation Headquarters
6931 Arlington Road Suite 200		Bethesda	MD	20814	131930701	501c(3)	$169,699,768	GENERAL SUPPORT
Emory University
1784 N Decatur Road		Atlanta	GA	30322	580566256	501c(3)	$276,403	CLINICAL RESEARCH CENTER
Emory University
1784 N Decatur Road	Suite 510	Atlanta	GA	30322	580566256	501c(3)	$577,263	CLINICAL RESEARCH STUDY
Fletcher Allen Health Care
111 Colchester Avenue	Suite 510	Burlington	VT	05401	030219309	501c(3)	$76,901	Clinical Res. Cntr
Kaiser Foundation Research Institute
1800 Harrison Street		Oakland	CA	94612	941105628	501c(3)	$128,693	Clinical Res. Cntr
Maine Medical Center
22 Bramhall Street	16th Floor	Portland	ME	041023175	010238552	501c(3)	$172,729	Clinical Res. Cntr
Medical University of South Carolina
PO Box 997		Charleston	SC	29402	576000722	501c(3)	$249,664	Clinical Res. Cntr
Medical University of South Carolina
PO Box 997		Charleston	SC	29402	576000722	501c(3)	$144,735	CLINICAL RESEARCH STUDY
Memorial Children's Hospital
2801 Atlantic Avenue		Long Beach	CA	90806	953527031	501c(3)	$153,306	Clinical Res. Cntr
Monmouth Medical Center Foundation
300 Second Avenue	ATTN Childrens Administration	Long Branch	NJ	07740	222456079	501c(3)	$124,365	Clinical Res. Cntr
National Jewish Medical and Research Center
1400 Jackson Street		Denver	CO	80206	742044647	501c(3)	$31,314	Clinical Res. Cntr
National Jewish Medical and Research Center
1400 Jackson Street		Denver	CO	80206	742044647	501c(3)	$338,641	CLINICAL RESEARCH STUDY
Nemours Children's Clinic - Jacksonville
807 Nira Street		Jacksonville	FL	32207	590634433	501c(3)	$395,887	Clinical Res. Cntr
Oregon Health & Science University
Sponsored Projects Administration O		Portland	OR	97239	237083114	501c(3)	$368,757	DRUG DISCOVERY AWARD
Pennsylvania State University
College of Medicine	0690 SW Bancroft Street	Hershey	PA	17033	246000376	IRC 115	$174,636	Clinical Res. Cntr
Philadelphia Health & Education Corp (Drexel Univ
3201 Arch Street	Office of Research Affairs H138	Philadelphia	PA	19104	232979433	501c(3)	$145,524	Clinical Res. Cntr
Providence Alaska Medical Center
4045 Lake Otis Pkwy 209	Suite 420	Anchorage	AK	99508	920016429	501c(3)	$117,238	Clinical Res. Cntr
Rainbow Babies and Children's Hospital
11100 Euclid Avenue		Cleveland	OH	44106	341018992	501c(3)	$23,675	ACADEMIC ADVISORY AWARD
Regents of the University of Colorado at Denver
Grants and Contracts Mail Stop F42	RBC Room 3001	Aurora	CO	80045	846000555	501c(3)	$20,621	ACADEMIC ADVISORY AWARD
Regents of the University of Colorado at Denver
Grants and Contracts Mail Stop F42	Anschutz Medical Campus Bldg 500	Aurora	CO	80045	846000555	501c(3)	$410,035	Clinical Res. Cntr
Regents of the University of Colorado at Denver
Grants and Contracts Mail Stop F42	Anschutz Medical Campus Bldg 500	Aurora	CO	80045	846000555	501c(3)	$65,409	CLINICAL RESEARCH
Research Foundation of SUNY on behalf of Upstate M
PO Box 9	Anschutz Medical Campus Bldg 500	Albany	NY	122010009	141368361	501c(3)	$319,823	Clinical Res. Cntr
Rosalind Franklin University of Medicine and Scien
Green Bay Road		North Chicago	IL	60064	362181973	501c(3)	$831,101	DRUG DISCOVERY AWARD
Sanford Children's Specialty Clinic
1600 W 22 Street		Sioux Falls	SD	57105	460447693	501c(3)	$115,862	Clinical Res. Cntr
Seattle Children's Hospital
4800 Sand Point Way NE		Seattle	WA	98105	910564748	501c(3)	$3,926,912	Clinical Res. Cntr
Seattle Children's Hospital
4800 Sand Point Way NE		Seattle	WA	98105	910564748	501c(3)	$5,027,754	CLINICAL RESEARCH
Seattle Children's Hospital
4800 Sand Point Way NE		Seattle	WA	98105	910564748	501c(3)	$1,272,310	CLINICAL RESEARCH STUDY
Seton Healthcare
4900 Mueller Blvd		Austin	TX	78723	741109643	501c(3)	$131,806	Clinical Res. Cntr
Spectrum Health Foundation
100 Michigan Street NE MC004	DCMC Administration 3rd Floor	Grand Rapids	MI	49503	382752328	501c(3)	$168,908	Clinical Res. Cntr
St Louis University
3500 Lindell Blvd		St Louis	MO	63103	430654872	501c(3)	$136,399	Clinical Res. Cntr
St Luke's Regional Medical Center
100 East Idaho		Boise	ID	83712	820161600	501c(3)	$150,313	Clinical Res. Cntr
Texas Tech University Health Sciences Center
3601 4th Street Stop 6540	Suite 200	Lubbock	TX	79430	752668014	IRC 115	$219,644	DRUG DISCOVERY AWARD
The Children's Hospital of Philadelphia
34th and Civic Center Boulevard		Philadelphia	PA	19104	231352166	501c(3)	$252,532	Clinical Res. Cntr
The Children's Hospital of Philadelphia
34th and Civic Center Boulevard		Philadelphia	PA	19104	231352166	501c(3)	$295,987	CLINICAL RESEARCH STUDY
The Children's Mercy Hospital
2401 Gillham Road		Kansas City	MO	61408	440605373	501c(3)	$185,991	Clinical Res. Cntr
The Feinstein Institute for Medical Research
350 Community Drive		Manhasset	NY	11030	112673595	501c(3)	$244,760	Clinical Res. Cntr
The General Hospital Corporation (Massachusetts Ge
PO Box 414876		Boston	MA	022414876	042697983	501c(3)	$162,676	Clinical Res. Cntr
The General Hospital Corporation (Massachusetts Ge
Mass General Research Finance		Boston	MA	02114	042697983	501c(3)	$163,500	CLINICAL RESEARCH STUDY
The Hitchcock Foundation
One Medical Center Drive	PO Box 414876	Lebanon	NH	03756	020222139	501c(3)	$171,899	Clinical Res. Cntr
The Johns Hopkins University
600 N Wolfe Street Park 316		Baltimore	MD	21205	520595110	501c(3)	$210,203	DRUG DISCOVERY AWARD
The Johns Hopkins University
600 N Wolfe Street Park 316		Baltimore	MD	21205	520595110	501c(3)	$399,404	Clinical Res. Cntr
The Johns Hopkins University
600 N Wolfe Street Park 316		Baltimore	MD	21205	520595110	501c(3)	$2,103,730	CLINICAL RESEARCH STUDY
The Medical College of Wisconsin
8701 Watertown Plank Road		Milwaukee	WI	53226	390806261	501c(3)	$180,901	Clinical Res. Cntr
The Rector and Visitors of the University of Virgi
Office of Sponsored Programs		Charlottesville	VA	229044195	546001796	501c(3)	$129,862	Clinical Res. Cntr
The Regents of the University of California San D
9500 Gilman Drive 0934	PO Box 400195	La Jolla	CA	920930984	956006144	501c(3)	$108,000	DRUG DISCOVERY AWARD
The Regents of the University of California San D
9500 Gilman Drive 0934		La Jolla	CA	920930984	956006144	501c(3)	$166,244	Clinical Res. Cntr
The Regents of The University of Michigan
3003 South State Street		Ann Arbor	MI	481091274	386006309	501c(3)	$218,733	Clinical Res. Cntr
The Regents of The University of Michigan
3003 South State Street	Room 1044	Ann Arbor	MI	481091274	386006309	501c(3)	$459,442	CLINICAL RESEARCH STUDY
The Regents of the University of Minnesota
Sponsored Projects Administration	Room 1044	Minneapolis	MN	554552070	416007513	501c(3)	$30,510	ACADEMIC ADVISORY AWARD
The Regents of the University of Minnesota
Sponsored Projects Administration	200 Oak Street SE Suite 450	Minneapolis	MN	554552070	416007513	501c(3)	$273,386	Clinical Res. Cntr
The Research Institute at Nationwide Children's Ho
700 Childrens Drive	200 Oak Street SE Suite 450	Columbus	OH	43205	316056230	501c(3)	$37,594	DRUG DISCOVERY AWARD
The Research Institute at Nationwide Children's Ho
700 Childrens Drive		Columbus	OH	43205	316056230	501c(3)	$299,996	Clinical Res. Cntr
The Scripps Research Institute
10666 North Torrey Pines Road		La Jolla	CA	92037	330435954	501c(3)	$84,000	DRUG DISCOVERY AWARD
The Toledo Hospital
2142 N Cove Blvd		Toledo	OH	43606	344428256	501c(3)	$136,941	Clinical Res. Cntr
The Trustees of Columbia University in the City of
PO Box 29789		New York	NY	100879789	135598093	501c(3)	$36,039	ACADEMIC ADVISORY AWARD
The Trustees of Columbia University in the City of
PO Box 29789	General Post Office	New York	NY	100879789	135598093	501c(3)	$205,400	DRUG DISCOVERY AWARD
The Trustees of Columbia University in the City of
PO Box 29789	General Post Office	New York	NY	100879789	135598093	501c(3)	$194,938	Clinical Res. Cntr
The University of Alabama at Birmingham
1530 3rd Avenue S THT422	General Post Office	Birmingham	AL	352940006	636005396	501c(3)	$113,518	ACADEMIC ADVISORY AWARD
The University of Alabama at Birmingham
1530 3rd Avenue S THT422		Birmingham	AL	352940006	636005396	501c(3)	$1,077,637	DRUG DISCOVERY AWARD
The University of Alabama at Birmingham
1530 3rd Avenue S THT422		Birmingham	AL	352940006	636005396	501c(3)	$776,786	Clinical Res. Cntr
The University of Alabama at Birmingham
1530 3rd Avenue S THT422		Birmingham	AL	352940006	636005396	501c(3)	$28,204	CLINICAL RESEARCH
The University of Alabama at Birmingham
1530 3rd Avenue S THT422		Birmingham	AL	352940006	636005396	501c(3)	$238,433	CLINICAL RESEARCH STUDY
The University of Chicago
University Research Administration		Chicago	IL	60637	362177139	501c(3)	$25,521	ACADEMIC ADVISORY AWARD
The University of Iowa
Office of Vice President for Resear	970 E 58th Street	Iowa City	IA	52242	426004813	501c(3)	$701,179	DRUG DISCOVERY AWARD
The University of Iowa
Office of Vice President for Resear	Division of Sponsored Programs	Iowa City	IA	52242	426004813	501c(3)	$172,582	Clinical Res. Cntr
The University of North Carolina at Chapel Hill
300 Bynum Hall	Division of Sponsored Programs	Chapel Hill	NC	275994100	566001393	501c(3)	$1,135,682	DRUG DISCOVERY AWARD
The University of North Carolina at Chapel Hill
300 Bynum Hall	CB 4100	Chapel Hill	NC	275994100	566001393	501c(3)	$366,750	Clinical Res. Cntr
The University of North Carolina at Chapel Hill
300 Bynum Hall	CB 4100	Chapel Hill	NC	275994100	566001393	501c(3)	$353,872	CLINICAL RESEARCH
The University of North Carolina at Chapel Hill
300 Bynum Hall	CB 4100	Chapel Hill	NC	275994100	566001393	501c(3)	$107,983	CLINICAL RESEARCH STUDY
The University of Utah
201 S Presidents Circle	CB 4100	Salt Lake City	UT	84112	876000525	501c(3)	$232,562	Clinical Res. Cntr
The University of Utah
201 S Presidents Circle	Room 406	Salt Lake City	UT	84112	876000525	501c(3)	$458,269	CLINICAL RESEARCH STUDY
The University of Vermont and State Agricultural C
Grant and Contract Administrative S	Room 406	Burlington	VT	05405	030179440	501c(3)	$84,531	Clinical Res. Cntr
Trustee of Indiana University
Financial Management Services	223 Waterman Bldg	Indianapolis	IN	462666057	356001673	501c(3)	$341,287	Clinical Res. Cntr
Trustees of Dartmouth College
Dartmouth Medical School	PO Box 66057	Hanover	NH	037551404	020222111	501c(3)	$91,000	CLINICAL RESEARCH STUDY
Trustees of Indiana University
Financial Management Services	Dept of Microbiology and Immunolog	Indianapolis	IN	462666057	356001673	501c(3)	$62,562	CLINICAL RESEARCH STUDY
University at Buffalo Pediatric Associates
239 Bryant Street	PO Box 66057	Buffalo	NY	14222	161238821	501c(3)	$93,900	ACADEMIC ADVISORY AWARD
University of Arkansas for Medical Sciences
4301 West Markham Street	2nd Floor	Little Rock	AR	72205	716046242	501c(3)	$161,990	Clinical Res. Cntr
University of Colorado Health Sciences Center
4200 E 9th Avenue	Mail Slot 555	Denver	CO	80262	846000555	501c(3)	$107,965	CLINICAL RESEARCH STUDY
University of Florida
Shands Childrens Hospital		Gainesville	FL	32610	596002052	IRC 115	$126,106	Clinical Res. Cntr
University of Kansas Medical Center Research Insti
3901 Rainbow Boulevard MSN 1039	1600 SW Archer Road Suite D2-15	Kansas City	KS	661032937	481108830	501c(3)	$117,369	Clinical Res. Cntr
University of Kentucky Research Foundation
337 Peterson		Lexington	KY	405060005	616033693	501c(3)	$156,093	Clinical Res. Cntr
University of Massachusetts Medical School
55 Lake Avenue North		Worcester	MA	01655	043167352	IRC 115	$61,873	Clinical Res. Cntr
University of Miami
PO Box 025405		Miami	FL	331025405	590624458	501c(3)	$141,491	Clinical Res. Cntr
University of Nebraska Medical Center
985100 Nebraska Medical Center		Omaha	NE	681985190	470491233	501c(3)	$174,495	Clinical Res. Cntr
University of Oklahoma Health Sciences Center
PO Box 26901		Oklahoma City	OK	73190	736017987	IRC 115	$159,737	Clinical Res. Cntr
University of Pittsburgh
350 Thackeray Hall		Pittsburgh	PA	15260	250965591	501c(3)	$543,899	DRUG DISCOVERY AWARD
University of Pittsburgh
350 Thackeray Hall		Pittsburgh	PA	15260	250965591	501c(3)	$316,235	Clinical Res. Cntr
University of Rochester
Box 649		Rochester	NY	14642	160743209	501c(3)	$141,013	Clinical Res. Cntr
University of Washington
Office of Sponsored Programs	601 Elmwood Avenue	Seattle	WA	981056692	916001537	IRC 115	$34,206	ACADEMIC ADVISORY AWARD
University of Washington
Office of Sponsored Programs	4333 Brooklyn Avenue NE	Seattle	WA	981056692	916001537	IRC 115	$31,748	DRUG DISCOVERY AWARD
University of Washington
Office of Sponsored Programs	4333 Brooklyn Avenue NE	Seattle	WA	981056692	916001537	IRC 115	$87,627	Clinical Res. Cntr
University of Washington
Office of Sponsored Programs	4333 Brooklyn Avenue NE	Seattle	WA	981056692	916001537	IRC 115	$47,846	CLINICAL RESEARCH STUDY
UT Southwestern Medical Center at Dallas
5323 Harry Hines Boulevard	4333 Brooklyn Avenue NE	Dallas	TX	753909105	756002868	IRC 115	$87,330	DRUG DISCOVERY AWARD
UT Southwestern Medical Center at Dallas
5323 Harry Hines Boulevard		Dallas	TX	753909105	756002868	IRC 115	$191,642	Clinical Res. Cntr
Vanderbilt University
PO Box 30195		Nashville	TN	372410195	620476822	501c(3)	$179,638	Clinical Res. Cntr
Virginia Commonwealth University
Box 2506 - VCU Station		Richmond	VA	232842506	546001758	501c(3)	$120,801	Clinical Res. Cntr
Virginia Commonwealth University
Box 2506 - VCU Station		Richmond	VA	232842506	546001758	501c(3)	$37,800	CLINICAL RESEARCH STUDY
Washington University
660 S Euclid Avenue		St Louis	MO	63110	430653611	501c(3)	$263,144	Clinical Res. Cntr
Washington University
Campus Box 1034		St Louis	MO	631121408	430653611	501c(3)	$12,903	CLINICAL RESEARCH STUDY
Wayne State University
Grants Contracts Office III	700 Rosedale Avenue	Detroit	MI	48201	383028425	501c(3)	$162,044	Clinical Res. Cntr
West Virginia University Research Corporation
WVU	Research and Sponsored Programs	Morgantown	WV	265066001	550665758	501C(3)	$130,397	Clinical Res. Cntr
ALBANY MEDICAL COLLEGE
47 NEW SCOTLAND AVENUE	MAIL CODE 88	ALBANY	NY	12208	141338310	501C(3)	$154,667	CLINICAL RES. CNTR
ALL CHILDREN'S HOSPITAL
DEPT 9010	PO BOX 31020	ST PETERSBURG	FL	33731	590683252	501C(3)	$171,501	CLINICAL RES. CNTR

Field	Value	IRS element (for citing)
Total501c3 Org	85	Total501c3OrgCnt

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	PART I, LINE 2	FormAndLineReferenceDesc
Explanation	THE ORGANIZATION HAS PROCEDURES IN PLACE TO MONITOR THE SCIENTIFIC PROGRESS AND FINANCIAL ASPECTS OF GRANT FUNDS AWARDED TO ENTITIES INSIDE OF THE US. SPONSORED INSTITUTIONS ARE REQUIRED TO SUBMIT ANNUAL REPORTS OF EXPENDITURES AS WELL AS SCIENTIFIC PROGRESS REPORTS. SCIENTIFIC REPORTS ARE REVIEWED BY THE ORGANIZATION'S SCIENTIFIC STAFF TO ENSURE ACCEPTABLE PROGRESS HAS BEEN ATTAINED. THE FINAL GRANT PAYMENT IS CONTINGENT UPON RECEIPT AND APPROVAL OF THE REPORT OF EXPENDITURES. REPORTS OF EXPENDITURES ARE REVIEWED AND APPROVED BY STAFF TO ENSURE INCURRED COSTS ARE APPROPRIATE. THE ORGANIZATION'S INTERNAL AUDITORS AUDIT A SAMPLE OF GRANT EXPENDITURE REPORTS BY EXAMINING SUPPORTING RECORDS FROM THE SPONSORED INSTITUTIONS.	ExplanationTxt

Schedule J IRS990ScheduleJ

Field	Value	IRS element (for citing)
Compensation Committee	Yes (X)	CompensationCommitteeInd
Independent Consultant	Yes (X)	IndependentConsultantInd
Form990 Of Other Organizations	Yes (X)	Form990OfOtherOrganizationsInd
Written Employment Contract	Yes (X)	WrittenEmploymentContractInd
Compensation Survey	Yes (X)	CompensationSurveyInd
Board Or Committee Approval	Yes (X)	BoardOrCommitteeApprovalInd
Severance Payment	false	SeverancePaymentInd
Supplemental Nonqual Rtr Plan	Yes (true)	SupplementalNonqualRtrPlanInd
Equity Based Comp Arrngm	false	EquityBasedCompArrngmInd
Comp Based On Revenue Of Flng Org	false	CompBasedOnRevenueOfFlngOrgInd
Comp Bsd On Rev Related Orgs	false	CompBsdOnRevRelatedOrgsInd
Comp Bsd Net Earns Flng Org	false	CompBsdNetEarnsFlngOrgInd
Comp Bsd Net Earns Rltd Orgs	false	CompBsdNetEarnsRltdOrgsInd
Any Non Fixed Payments	Yes (true)	AnyNonFixedPaymentsInd
Initial Contract Exception	false	InitialContractExceptionInd

Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (8 entries)

TitleTitleTxt	Base Compensation Filing OrgBaseCompensationFilingOrgAmt	Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt	Bonus Filing OrganizationBonusFilingOrganizationAmount	Bonus Related OrganizationsBonusRelatedOrganizationsAmt	Other Compensation Filing OrgOtherCompensationFilingOrgAmt	Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt	Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt	Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt	Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt	Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt	Total Compensation Filing OrgTotalCompensationFilingOrgAmt	Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt	Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt	Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt
Robert J Beall PhD
President & CEO	$190,871	$380,301	$165,543	$336,101	$8,150	$20,911	$71,686	$171,595	$0	$18,506	$436,250	$927,414	$95,519	$193,934
Preston W Campbell MD
Exec VP of Medical Affairs	$129,788	$254,125	$110,254	$223,848	$154,197	$318,935	$49,994	$127,555	$0	$25,365	$444,233	$949,828	$170,280	$345,168
C Richard Mattingly
Exec VP, COO AND SECRETARY	$0	$387,406	$0	$341,899	$0	$23,165	$0	$203,248	$0	$17,506	$0	$973,224	$0	$215,658
Vera H Twigg
EXEC VP and CFO	$0	$292,024	$0	$174,583	$0	$20,244	$0	$66,034	$0	$25,315	$0	$578,200	$0	$90,322
BRUCE MARSHALL MD
SR. VP OF CLINICAL AFFAIRS	$312,200	$0	$63,561	$0	$3,564	$0	$31,052	$0	$500	$0	$410,877	$0	$0	$0
THEODORE J TORPHY PHD
HEAD OF RESEARCH STRATEGY	$215,600	$0	$0	$0	$0	$0	$0	$0	$0	$0	$215,600	$0	$0	$0
MARTIN MENSE
PRINCIPAL SCIENTIST DRUG DISC	$154,409	$0	$27,830	$0	$3,234	$0	$18,037	$0	$24,883	$0	$228,393	$0	$0	$0
Hermann Bihler PHD
Senior Scientist	$135,869	$0	$10,270	$0	$414	$0	$12,989	$0	$0	$0	$159,542	$0	$0	$0

Supplemental Information Detail SupplementalInformationDetail (2 entries)

Form And Line ReferenceFormAndLineReferenceDesc

ExplanationExplanationTxt

PART I, LINE 4B and Line 7

Part I, Line 4b: Certain persons listed in Form 990, Part VII, Section A participate in a nonqualified deferred compensation plan, under which interests are forfeited by the participant if the participant voluntarily terminates employment prior to the designated vesting date. Further information about the nonqualified deferred compensation plan in which those persons participate is provided in the additional information for Schedule J, Part II, below. Part I, Line 7: Several individuals listed in Form 990, Part VII, Section A, line 1a, (who are identified in Part II, below) participated in an Incentive Compensation Plan, from which non-fixed payments not described in lines 5 and 6 were paid. The Plan is sponsored by CFF, a related organization. The individuals participate by virtue of being officers of CFF. However, if an individual also is an officer of CFFT and receives compensation from CFFT, a portion of the individual's award is paid by CFFT. The Incentive Compensation Plan pays non-fixed payments subject to, and based on, the achievement of annual performance objectives established in advance by the Compensation Committee. In addition, the Incentive Compensation Plan pays non-fixed payments that relate to a three-year performance period, subject to, and based on, the achievement of long-term performance objectives established in advance by the Compensation Committee. Any financial performance objectives established under the Incentive Compensation Plan do not include royalty-related revenues (such as royalty streams, lump-sum royalty payments and sales proceeds of royalty rights) related to CF drugs.

PART II

Cystic Fibrosis Foundation Therapeutics, Inc. (A) Name: R. Beall, Ph.D.; (B)(i) Base Compensation: base salary - $183,281, 401(k) bonus - $7,590; (B)(ii) Bonus & Incentive Compensation: annual incentive plan benefit (1) - $63,900, long-term incentive plan payment, of which $95,519 was previously reported (6) - $101,643; (B)(iii) Other Reportable Compensation: health insurance benefit - $1,649, automobile allowance - $2,376, other benefits - $4,125 (C) Deferred Compensation: long-term incentive plan benefit (6) - $39,346, SERP (4) - $32,340; (D) Nontaxable Benefits: $0 Cystic Fibrosis Foundation - Headquarters. EIN 13-1930701. (A) Name: R. Beall, Ph.D.; (B)(i) Base Compensation: base salary - $364,891, 401(k) bonus - $15,410; (B)(ii) Bonus & Incentive Compensation: annual incentive plan benefit (1) - $129,736, long-term incentive plan payment, of which $193,934 was previously reported (6) - $206,365; (B)(iii) Other Reportable Compensation: health insurance benefit - $3,349, automobile allowance - $4,824, other benefits including taxable general organization group term life insurance premium - $12,738; (C) Deferred Compensation: retirement benefit (2) - $26,052, long-term incentive plan benefit (6) - $79,883, SERP (4) - $65,660; (D) Nontaxable Benefits: employer contribution to general organization health plan benefit - $11,282, employee contribution to flexible spending account benefit - $2,500, employee contribution to general organization health plan benefit - $4,724 Cystic Fibrosis Foundation Therapeutics, Inc. EIN 91-2059167. (A) Name: P. Campbell, M.D.; (B)(i) Base Compensation: base salary - $129,788; (B)(ii) Bonus & Incentive Compensation: annual incentive plan benefit (1) - $35,431, long-term incentive plan payment, of which $70,315 was previously reported (6) - $74,823; (B)(iii) Other Reportable Compensation: Section 457(b) Plan (5) - $5,775, SERP account that became vested, of which $99,695 was previously reported (3) - $148,422; (C) Deferred Compensation: long-term incentive plan benefit (6) - $29,501, SERP (4) - $20,493; (D) Nontaxable Benefits: $0 Cystic Fibrosis Foundation - Headquarters. EIN 13-1930701. (A) Name: P. Campbell, M.D.; (B)(i) Base Compensation: base salary - $254,125; (B)(ii) Bonus & Incentive Compensation: annual incentive plan benefit (1) - $71,937, long-term incentive plan payment, of which $142,760 was previously reported (6) - $151,911; (B)(iii) Other Reportable Compensation: other benefits including taxable general organization group term life insurance premium - $5,867, Section 457(b) Plan (5) - $11,725, SERP account that became vested, of which $202,408 was previously reported (3) - $301,343; (C) Deferred Compensation: retirement benefit (2) - $26,052, long-term incentive plan benefit (6) - $59,896, SERP (4) - $41,607; (D) Nontaxable Benefits: employer contribution to general organization health plan benefit - $15,982, employee contribution to flexible spending account benefit - $2,500, employee contribution to general organization health plan benefit - $6,883 Cystic Fibrosis Foundation - Headquarters. EIN 13-1930701. Name: (A) R. Mattingly; (B)(i) Base Compensation: base salary - $387,406; (B)(ii) Bonus & Incentive Compensation: annual incentive plan benefit (1) - $112,417, long-term incentive plan payment, of which $215,658 was previously reported (6) - $229,482; (B)(iii) Other Reportable Compensation: Section 457(b) Plan (5) - $17,500; other benefits including taxable general organization group term life insurance premium - $5,665; (C) Deferred Compensation: retirement benefit (2) - $26,052, long-term incentive plan benefit (6) - $88,833, SERP (4) - $88,363; (D) Nontaxable Benefits: employer contribution to general organization health plan benefit - $11,282, employee contribution to flexible spending account benefit - $1,500, employee contribution to general organization health plan benefit - $4,724 Cystic Fibrosis Foundation - Headquarters. EIN 13-1930701. (A) Name: V. Twigg; (B)(i) Base Compensation: base salary - $292,024; (B)(ii) Bonus & Incentive Compensation: annual incentive plan benefit (1) - $78,471, long-term incentive plan payment, of which $90,322 was previously reported (6) - $96,112; (B)(iii) Other Reportable Compensation: taxable general organization group term life insurance premium - $2,744, Section 457(b) Plan (5) - $17,500; (C) Deferred Compensation: retirement benefit (2) - $26,052, long-term incentive plan benefit (6) - $35,067, SERP (4) - $4,915; (D) Nontaxable Benefits: employer contribution to general organization health plan benefit - $15,982, employee contribution to flexible spending account benefit - $2,500, employee contribution to general organization health plan benefit - $6,833 (1) This is an award subject to, and based on, achievement of annual performance standards established in advance by the Compensation Committee of the CFF Board. (2) This is the employer contribution made under the Cystic Fibrosis Foundation 401(k) Plan for the 2013 Plan Year. (3) This amount is the aggregate of employer contributions to the SERP that were earned by the participant and accrued from 2007 through 2012, and which became vested (but have not yet been paid, in accordance with the governing SERP documents) during the reporting year. As required, SERP contributions have been reported as "Contributions to Employee Benefit Plans" and "Deferred Compensation" on prior years' Form 990s and therefore (as required by the instructions) are double-reported here. (4) The SERP is sponsored by CFF, a related organization. The executive participates by virtue of being an officer of CFF. However, both CFFT and CFF make contributions on the executive's behalf if the executive receives compensation from CFFT (as an officer of CFFT) and from CFF (as an officer of CFF). A. This is an unvested employer contribution to the SERP. B. SERP interests are forfeited by the participant if the participant voluntarily terminates employment prior to attaining the vesting date designated by CFF (which is either a specified age or date, depending on the participant). C. SERP interests are held in a trust subject to the claims of CFF's bankruptcy creditors. In the event of a CFF bankruptcy, participants would become general unsecured creditors of CFF. D. The SERP is a nonqualified deferred compensation plan. This means that participants do not receive the tax benefits available to participants in tax qualified retirement plans. For example, under current law, interests under SERPs are reportable as taxable compensation when they become vested, even if those amounts are not yet payable to the participant (and even if those amounts are never paid to the participant). E. The SERP's design was reviewed and opined upon as reasonable by an independent compensation consultant. SERP contribution amounts were determined by an independent actuary. F. CFF retains the right to amend or terminate the SERP at any time. (5) The 457(b) Plan is sponsored by CFF, a related organization. The executive participates by virtue of being an officer of CFF. However, both CFFT and CFF make contributions on the executive's behalf if the executive receives compensation from CFFT (as an officer of CFFT) and from CFF (as an officer of CFF). A. This is a vested contribution to the 457(b) Plan for the reporting period. B. In the event of a CFF bankruptcy, participants are general unsecured creditors of CFF. C. Distributions from the 457(b) Plan may not be rolled-over to an IRA or qualified plan (but may only be rolled-over to another 457(b) plan). D. The 457(b) Plan's design was reviewed and opined upon as reasonable by an independent compensation consultant. An independent actuary developed the contribution formula pursuant to which 457(b) contribution amounts are determined. Contributions to the 457(b) Plan are subject to annual IRS limits (currently $17,500). E. CFF retains the right to amend or terminate the 457(b) Plan at any time. (6) This Plan provides for awards that relate to a three-year performance period, subject to, and based on, achievement of performance objectives established in advance by the Compensation Committee of the Board of Trustees of CFF, a related entity. The individuals participate by virtue of being officers of CFF. However, if an individual also is an officer of CFFT and receives compensation from CFFT, a portion of the individual's award is paid by CFFT. Any financial performance objectives established under the Incentive Compensation Plan do not include royalty-related revenues (such as royalty streams, lump-sum royalty payments and sales proceeds of royalty rights) related to CF drugs. Each year, a new three-year performance period begins. As required by the Form 990 instructions, the amounts reported on this Form 990 reflect an estimate of the portion of each award that the executive accrued under the Plan for performance in 2013 (i.e., with respect to the 2011-2013, 2012-2014 and the 2013-2015 performance

Schedule O IRS990ScheduleO

Supplemental Information Detail SupplementalInformationDetail (8 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
Part VI, Section A, Line 7a (Page 6 Core Form)	Certain of the Organization's board members are designated by the Board of Trustees of the Cystic Fibrosis Foundation.
Part VI, Section B, Line 11b (Page 6 Core Form)	The Organization's Board of Directors receives a draft of the Form 990 prior to its being filed, with sufficient time for review and comment allowed. The Organization's ERISA attorneys review the executive compensation sections of the Form 990 to ensure completeness and accuracy. The Audit Committee also reviews the Form 990 as part of its chartered responsibilities. In all cases the cystic fibrosis foundation therapeutics board of directors received a complete copy of the final form 990 before it is filed.
Part VI, Section B, Line 12c (Page 6 Core Form)	A conflict of interest disclosure statement is completed annually by each Board member and officer. As required within the bylaws, any potential conflicts of interest must be reported to the Board as they arise. When any matter is deemed a potential conflict of interest and requires action by the Board of DIRECTORS, the interested director or officer is required to retire from the room in which the Board is meeting, may not participate in the final deliberation of the matter, and may not vote on the matter. The Organization enforced the policy during 2013 and had no conflicts of interest as defined by the policy.
Part VI, Section B, Line 15a and 15b (Page 6 Core Form)	The total compensation of executives at the Organization is specifically designed to attract and retain the highest qualified executive and medical talent to fulfill the critically important mission of curing cystic fibrosis and providing all people with the disease the opportunity to lead full, productive lives. Cystic Fibrosis Foundation Therapeutics, Inc. shares officers with Cystic Fibrosis Foundation, a related organization. The independent Compensation Committee of the CF Foundation's Board of Trustees follows the process described in the IRS intermediate sanctions rules when determining compensation for executives of the Organization. Specifically, the Committee: (1) Is composed entirely of non-employee volunteer directors who have no familial, business or significant personal relationships with the Organization or its executives. (2) Assesses the short-term and long-term contribution and performance of each executive in meeting very definitive and quantifiable objectives focused on the Organization's mission success. (3) Engages an independent compensation consulting firm to compile appropriate comparability data (including compensation market information for peers with whom the Organization competes for executive talent) for Committee reliance. The Committee meets with representatives of the consulting firm to review this data in detail. (4) Reviews all elements of each executive's total compensation, including but not limited to base salary, bonuses, perquisites, fringe benefits, and incentive and deferred compensation arrangements. Upon the executive's hire, and at each point in time thereafter at which a new or revised compensation arrangement is under consideration with respect to the executive, the Committee meets with its independent compensation consulting firm before the arrangement is implemented to evaluate the reasonableness of the arrangement by comparing both the arrangement itself and the executive's entire compensation package to compensation packages paid by similarly situated organizations for functionally comparable positions. (5) Documents, concurrently with its determination, the basis for its determination in the minutes of its meeting. These minutes are reviewed, revised if necessary and approved at the following meeting of the Committee. (6) Obtains a written legal opinion concerning the Committee's compliance with the IRS intermediate sanctions rules. The process described above was used to establish compensation for the following positions: President & CEO Executive Vice President, COO and Secretary Executive Vice President for Medical Affairs Executive Vice President & CFO The process was last undertaken in 2012 (and again in 2014).
Part VI, Section C, Line 19 (Page 6 Core Form)	The Form 1023 for the Organization was available on its website, CFF.org, and the Organization's website provides a direct link to its Form 990 on Guidestar.org. CFFT's governing documents (Bylaws and Articles of Incorporation) are available upon request by contacting the Organization in writing or by phone. Information on how to obtain the governing documents is available on the website, www.cff.org/Research/CFFT. The Board and Officer Conflict of Interest Policy and the audited financial statements are available on the website, www.cff.org/Research/CFFT.
FORM 990, PART VII, SECTION A	NAME AND TITLE CHRISTY SHAFFER, PH.D, CHAIR AVG HRS WORKED 5 HRS AVG HRS WORKED - RELATED 6 HRS POSITION INDIVIDUAL DIRECTOR REPORTABLE COMP FROM THE ORG NONE REPORTABLE COMP FROM RELATED ORG NONE EST. AMT OF OTHER COMP FROM THE ORG NONE NAME AND TITLE JASON M. ARYEH, DIRECTOR AVG HRS WORKED 3 HRS POSITION INDIVIDUAL DIRECTOR REPORTABLE COMP FROM THE ORG NONE REPORTABLE COMP FROM RELATED ORG NONE EST. AMT OF OTHER COMP FROM THE ORG NONE NAME AND TITLE STEVEN SHAK, M.D., DIRECTOR AVG HRS WORKED 3 HRS AVG HRS WORKED - RELATED 6 HRS POSITION INDIVIDUAL DIRECTOR REPORTABLE COMP FROM THE ORG NONE REPORTABLE COMP FROM RELATED ORG NONE EST. AMT OF OTHER COMP FROM THE ORG NONE NAME AND TITLE CATHERINE C. MCLOUD, DIRECTOR AVG HRS WORKED 3 HRS AVG HRS WORKED - RELATED 11 HRS POSITION INDIVIDUAL DIRECTOR REPORTABLE COMP FROM THE ORG NONE REPORTABLE COMP FROM RELATED ORG NONE EST. AMT OF OTHER COMP FROM THE ORG NONE NAME AND TITLE JONATHAN COHN, M.D., DIRECTOR AVG HRS WORKED 3 HRS POSITION INDIVIDUAL DIRECTOR REPORTABLE COMP FROM THE ORG NONE REPORTABLE COMP FROM RELATED ORG NONE EST. AMT OF OTHER COMP FROM THE ORG NONE NAME AND TITLE D. PAUL FLESSNER, DIRECTOR AVG HRS WORKED 3 HRS POSITION INDIVIDUAL DIRECTOR REPORTABLE COMP FROM THE ORG NONE REPORTABLE COMP FROM RELATED ORG NONE EST. AMT OF OTHER COMP FROM THE ORG NONE NAME AND TITLE ROBERT J. BEALL, PH.D, PRES/CEO AVG HRS WORKED 20 HRS AVG HRS WORKED - RELATED 40 HRS POSITION INDIVIDUAL DIRECTOR & OFFICER REPORTABLE COMP FROM THE ORG 364,564 REPORTABLE COMP FROM RELATED ORG 737,313 EST. AMT OF OTHER COMP FROM THE ORG 261,787 NAME AND TITLE PRESTON W. CAMPBELL, M.D., EXEC VP OF MEDICAL AFFAIRS AVG HRS WORKED 20 HRS AVG HRS WORKED - RELATED 40 HRS POSITION OFFICER REPORTABLE COMP FROM THE ORG 394,239 REPORTABLE COMP FROM RELATED ORG 796,908 EST. AMT OF OTHER COMP FROM THE ORG 202,914 NAME AND TITLE C. RICHARD MATTINGLY EXEC VP, COO AND SECRETARY AVG HRS WORKED 5 HRS AVG HRS WORKED - RELATED 55 HRS POSITION OFFICER REPORTABLE COMP FROM THE ORG NONE REPORTABLE COMP FROM RELATED ORG 752,470 EST. AMT OF OTHER COMP FROM THE ORG 220,754 NAME AND TITLE VERA H. TWIGG, EXEC VP & CFO AVG HRS WORKED 5 HRS AVG HRS WORKED - RELATED 55 HRS POSITION OFFICER REPORTABLE COMP FROM THE ORG NONE REPORTABLE COMP FROM RELATED ORG 486,851 EST. AMT OF OTHER COMP FROM THE ORG 91,349 NAME AND TITLE BRUCE MARSHALL, MD, SR. VP OF CLINICAL AFFAIRS AVG HRS WORKED 50 HRS POSITION HIGHEST COMPENSATED EMPLOYEE REPORTABLE COMP FROM THE ORG 379,325 REPORTABLE COMP FROM RELATED ORG NONE EST. AMT OF OTHER COMP FROM THE ORG 31,552 NAME AND TITLE THEODORE TORPHY, PH.D. HEAD OF RESEARCH STRATEGY AVG HRS WORKED 50 HRS POSITION HIGHEST COMPENSATED EMPLOYEE REPORTABLE COMP FROM THE ORG 215,600 REPORTABLE COMP FROM RELATED ORG NONE EST. AMT OF OTHER COMP FROM THE ORG NONE NAME AND TITLE MARTIN MENSE, PH.D, PRINCIPAL SCIENTIST FOR DRUG DISCOVERY AVG HRS WORKED 50 HRS POSITION HIGHEST COMPENSATED EMPLOYEE REPORTABLE COMP FROM THE ORG 182,563 REPORTABLE COMP FROM RELATED ORG NONE EST. AMT OF OTHER COMP FROM THE ORG 42,921 NAME AND TITLE HERMANN BIHLER, PH.D., SENIOR SCIENTIST AVG HRS WORKED 50 HRS POSITION HIGHEST COMPENSATED EMPLOYEE REPORTABLE COMP FROM THE ORG 146,553 REPORTABLE COMP FROM RELATED ORG NONE EST. AMT OF OTHER COMP FROM THE ORG 12,989 NAME AND TITLE CYNTHIA GEORGE, MDS, FNP, BC SR. DIR OF PaTIENT ENGAGEMENT AVG HRS WORKED 50 HRS POSITION HIGHEST COMPENSATED EMPLOYEE REPORTABLE COMP FROM THE ORG 127,454 REPORTABLE COMP FROM RELATED ORG NONE EST. AMT OF OTHER COMP FROM THE ORG 13,478 TOTAL REPORTABLE COMP FROM THE ORG 1,810,298 TOTAL REPORTABLE COMP FROM RELATED ORG 2,773,542 TOTAL EST. AMT OF OTHER COMP FROM THE ORG 877,744
FORM 990, PART VIII, LINE 5	CFFT retains legal and beneficial rights to intellectual property developed under certain scientific grants and drug discovery agreements. Royalties received under these agreements are recorded as revenue when they become due. In addition, at times CFFT may sell all or a portion of its royalty rights under certain of these agreements in exchange for a lump sum. Amounts received under these agreements are recorded as royalty revenue when rights are forfeited and proceeds are receivable. In May 2013, CFFT entered into an agreement to sell a portion of its future royalty revenue under one such drug discovery agreement. Royalty revenue incudes $247,900,946 relating to this transaction.
FORM 990, PART I, LINE 1	THE MISSION OF THE CYSTIC FIBROSIS FOUNDATION, A NONPROFIT DONOR SUPPORTED ORGANIZATION, IS TO CURE CYSTIC FIBROSIS AND TO PROVIDE ALL PEOPLE WITH THE DISEASE THE OPPORTUNITY TO LEAD FULL, PRODUCTIVE LIVES BY FUNDING RESEARCH AND DRUG DEVELOPMENT AND PROMOTING INDIVIDUALIZED TREATMENT.

Schedule R IRS990ScheduleR

Id Related Tax Exempt Org IdRelatedTaxExemptOrgGrp (2 entries)

Address Line1USAddress/AddressLine1	CityUSAddress/City	StateUSAddress/State	ZIP CodeUSAddress/ZIPCode	EINEIN	Primary ActivitiesPrimaryActivitiesTxt	Legal Domicile StateLegalDomicileStateCd	Exempt Code SectionExemptCodeSectionTxt	Public Charity StatusPublicCharityStatusTxt	Business Name Line1DirectControllingEntityName/BusinessNameLine1	Controlled OrganizationControlledOrganizationInd
CYSTIC FIBROSIS FOUNDATION-HEADQUARTERS
6931 ARLINGTON RD	bethesda	MD	20814	131930701	research	DE	501(c)(3)	7	na	false
CYSTIC FIBROSIS FOUNDATION - GROUP
6931 ARLINGTON RD	BETHESDA	MD	20814	136161105	EDUCATION	DE	501(c)(3)	7	CFF-HQ	false

Field	Value	IRS element (for citing)
Receipt Of Int Annts Rnts Rylts	false	ReceiptOfIntAnntsRntsRyltsInd
Gift Grnt Or Cap Contri To Oth Org	Yes (true)	GiftGrntOrCapContriToOthOrgInd
Gift Grnt Cap Contri From Oth Org	false	GiftGrntCapContriFromOthOrgInd
Loans Or Guarantees To Other Org	false	LoansOrGuaranteesToOtherOrgInd
Loans Or Guarantees From Oth Org	false	LoansOrGuaranteesFromOthOrgInd
Div Related Organization	false	DivRelatedOrganizationInd
Asset Sale To Other Org	false	AssetSaleToOtherOrgInd
Asset Purchase From Other Org	false	AssetPurchaseFromOtherOrgInd
Asset Exchange	false	AssetExchangeInd
Rental Of Facilities To Oth Org	false	RentalOfFacilitiesToOthOrgInd
Rental Of Fclts From Oth Org	false	RentalOfFcltsFromOthOrgInd
Perform Of Services For Oth Org	false	PerformOfServicesForOthOrgInd
Perform Of Services By Other Org	false	PerformOfServicesByOtherOrgInd
Sharing Of Facilities	Yes (true)	SharingOfFacilitiesInd
Paid Employees Sharing	Yes (true)	PaidEmployeesSharingInd
Reimbursement Paid To Other Org	false	ReimbursementPaidToOtherOrgInd
Reimbursement Paid By Other Org	false	ReimbursementPaidByOtherOrgInd
Transfer To Other Org	false	TransferToOtherOrgInd
Transfer From Other Org	false	TransferFromOtherOrgInd

Transactions Related Org TransactionsRelatedOrgGrp (3 entries)

Transaction TypeTransactionTypeTxt	InvolvedInvolvedAmt	Method Of Amount DeterminationMethodOfAmountDeterminationTxt
Cystic fibrosis foundation - headquarters
B	$169,699,768	FMV
Cystic fibrosis foundation - headquarters
N	$520,100	cost
Cystic fibrosis foundation - headquarters
O	$2,365,047	cost